来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

休市中 06-12 16:08:21

9.460

+0.470

+5.23%

最高9.670	最低8.790	成交量330.75万
今开9.090	昨收8.990	日振幅9.79%
总市值42.48亿	流通市值42.48亿	总股本4.49亿
成交额3,099万	换手率0.74%	流通股本4.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":9.46,"timestamp":1781251701003,"preClose":8.99,"halted":0,"volume":3307500,"delay":0,"changeRate":0.05228031145717471,"floatShares":449000000,"shares":449000000,"eps":-0.59,"marketStatus":"休市中","change":0.47,"latestTime":"06-12 16:08:21","open":9.09,"high":9.67,"low":8.79,"amount":30985790,"amplitude":0.097887,"askPrice":9.48,"askSize":23500,"bidPrice":9.46,"bidSize":11000,"shortable":3,"etf":0,"ttmEps":-0.565,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":7,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":8.99,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":0.9276977478686049,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"2642072259","title":"港股异动 | 来凯医药-B(02105)涨超5% 近日就LAE118与Vasque Bio签订全球独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2642072259","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642072259?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:37","pubTimestamp":1781235478,"startTime":"0","endTime":"0","summary":"消息面上，来凯医药-B发布公告，于2026年6月9日，本集团与Vasque Bio,Inc.签订了一项独家许可协议。作为回报，本集团有权获得一笔不可退还且不可抵扣的首付现金款项1000万美元，以及在无需额外对价的情况下，有权获得Vasque Bio已发行普通股最多达高双位数百分比的股权，或替代该等普通股的现金付款。如Vasque Bio达成符合特定条件的合格战略合作或收购交易，本集团将有权获得额外付款，金额最高可达该战略交易价值的50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02105","VXUS","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642047201","title":"5.27亿美元！来凯医药（02105）黄金靶点，站上NewCo 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2642047201","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642047201?lang=zh_cn&edition=full","pubTime":"2026-06-11 08:37","pubTimestamp":1781138277,"startTime":"0","endTime":"0","summary":"康诺亚CM3362024年以NewCo交易出海，首付款仅1600万美元，但NewCo公司今年被吉利德以21.75亿美元收购，康诺亚斩获2.57亿美元首付款。来凯LAE118出海首付款为1000万美元，但Vasque Bio后续若被收购，来凯分成比例最高达50%。作为经典的黄金靶点，PI3Kα仍在赶赴大药之旅。诺华Alpelisib自2019年获批上市以来，销售峰值止步于5亿美元级别。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GLL","GCmain","FGDL","GDXD","GLD","1OZmain","NUGT","SGOL","GOLY","DGP","MGCmain","BEGS","IAUI","GOAU","IAU","DBC","SGUmain","GDXJ","JDST","XME","SGDM","JNUG","CEF","QOmain","USG","GLDM","AAAU","GDXY","IAUM","GLTR","UGL","BTGD","RING","DZZ","BAR","PHYS","02105","UYM","SGCmain","SHNY","PALL","159831","GDXU","OUNZ","159934","PICK","GDX","DULL","GBUG","DUST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642641910","title":"1000万美元首付+5.17亿美元里程碑付款：来凯医药-B达成海外授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2642641910","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642641910?lang=zh_cn&edition=full","pubTime":"2026-06-10 09:31","pubTimestamp":1781055060,"startTime":"0","endTime":"0","summary":"6月10日，来凯医药-B（02105）发布公告，公司与VasqueBio,Inc.签订了一项独家许可协议，涉及其自主研发的新型PI3Kα泛突变选择性抑制剂LAE118。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606103766021358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642041563","title":"来凯医药-B(02105)与VASQUE BIO就LAE118签订中国以外地区的独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2642041563","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642041563?lang=zh_cn&edition=full","pubTime":"2026-06-10 08:15","pubTimestamp":1781050552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，于2026年6月9日，本集团与Vasque Bio,Inc.签订了一项独家许可协议。董事会认为，该许可协议的签订符合本公司及其股东的整体最佳利益。Vasque Bio主要专注于罕见疾病治疗药物的开发，本集团则专注于在授权区域以外开发LAE118的肿瘤疗法。获得Vasque Bio已发行普通股的权利，亦使本集团能够保留LAE118未来的增值潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BIO","02105","LU1169590202.USD","LU1169589451.USD","BK1161","BK4585","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142079456","title":"来凯医药-B更新5月股份变动月报表，已发行普通股增至449,331,350股","url":"https://stock-news.laohu8.com/highlight/detail?id=1142079456","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142079456?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:06","pubTimestamp":1780563992,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年6月4日公布截至2026年5月31日的股份变动月报表。本月报显示，公司注册股本未发生变动，仍为5,000,000,000股普通股，面值每股0.00001美元，总注册股本50,000美元。报告期内，公司已发行股本由原先的446,466,350股增加至449,331,350股，新增发行2,865,000股普通股。公司本月无股份购回或注销活动，库藏股余额保持为0股。期末普通股股本总数变动为449,331,350股。本次公告由来凯医药有限公司联席公司秘书柯晨煜签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138972669","title":"来凯医药-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1138972669","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138972669?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:56","pubTimestamp":1778770575,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于5月14日发布公告，董事会建议于6月5日举行的股东周年大会上，寻求一般授权回购不超过公司于决议案通过当日已发行股本的10%。截至最后可行日期，公司已发行股份总数约为449,331,350股，若该授权获股东会议通过且在此期间无新增发行或回购，公司可回购的股份数量最高可达44,933,135股。公司股东周年大会订于2026年6月5日召开，并将于2026年6月2日至2026年6月5日暂时停止办理股份过户登记，股东及投资者可关注相关日程安排。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635761328","title":"港股异动 | 来凯医药-B(02105)午前涨超5% LAE002 III期临床到达终点 将提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2635761328","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635761328?lang=zh_cn&edition=full","pubTime":"2026-05-14 11:58","pubTimestamp":1778731118,"startTime":"0","endTime":"0","summary":"消息面上，来凯医药核心产品AKT抑制剂LAE002治疗乳腺癌的III期临床试验已于4月15日宣布达到主要终点。根据公司计划，将协同合作伙伴齐鲁制药于近期向国家药监局提交新药上市申请。齐鲁制药也于4月30日宣布将推进该药的国内上市申请。作为回报，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4585","VXUS","BK1161","IPOS","02105","BK4588","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635243220","title":"MSCI全球小盘股指数5月调整：美图公司(01357)等14只股票获纳入 剑桥科技(06166)等21只被剔除","url":"https://stock-news.laohu8.com/highlight/detail?id=2635243220","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635243220?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:01","pubTimestamp":1778637673,"startTime":"0","endTime":"0","summary":"此外，MSCI全球小盘股指数于中国香港地区纳入来凯医药、美华创富、珩湾科技，同时剔除百富环球、数码通电讯。纳入或剔除MSCI全球小盘股指数意味着股票将被全球主流机构投资者重点关注或移出其投资组合，直接影响公司的国际资本关注度、资金流向与市场流动性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SRTY","LU0164939612.USD","09899","02373","BK1095","LU0289961442.SGD","00347","06166","BK4585","000898","LU0231459107.USD","BK4112","BK4581","BK1128","IE0009570106.USD","MNQmain","MSCI","LU0511384066.AUD","LU0620787316.HKD","LU0708995401.HKD","01357","603083","BK1149","RSSL","00772","UWM","BK1613","00315","BK4534","06196","BK4550","LU0082770016.USD","LU1267930730.SGD","00327","BK1615","LU2210150020.SGD","LU0278937759.USD","IWN","LU0175139822.USD","IWMI","LU2125910849.SGD","AVUV","LU2210149790.SGD","00357","BK1609","RYLD","BK0214","IWF","LU0109391861.USD","MGRT","02105","LU0289739343.SGD","LU0082770016.SGD","LU2045819591.USD","09985","VTWO","LU0672654240.SGD","RWM","VB","IE00BKPKM429.USD","LU2125910500.SGD","01523","BK1240","01515","BK4588","LU0289960550.SGD","002936","LU1691799644.USD","LU1804176565.USD","BK4535","BK1618","LU2265009873.SGD","LU0320765059.SGD","LU2095319765.USD","TWM","BK1612","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634408851","title":"港股异动 | 来凯医药-B(02105)午后涨超10% 齐鲁制药推进LAE002上市申请 公司有望获首付款及里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2634408851","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634408851?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:32","pubTimestamp":1778481147,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B午后涨超10%，截至发稿，涨9.63%，报14.8港元，成交额6089.13万港元。4月30日，齐鲁制药官方宣布，由其独家引进中国区域研发与商业化权益的创新靶向药afuresertib临床研究达到主要终点，齐鲁制药独家引进推进国内上市申请。作为回报，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105","BK4588","VXUS","BK1191","IPOS","01477","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634422784","title":"来凯医药-B(02105)发行合共286.5万股以满足根据2024年股份奖励计划授予的RSU的归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2634422784","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634422784?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:06","pubTimestamp":1778458011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，于2026年5月8日，该公司发行合共286.5万股普通股以满足根据2024年股份奖励计划授予的RSU的归属。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147680970","title":"来凯医药-B：根据2024年股份奖励计划发行2,865,000股新股，已发行股本增至449,331,350股","url":"https://stock-news.laohu8.com/highlight/detail?id=1147680970","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147680970?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:02","pubTimestamp":1778457723,"startTime":"0","endTime":"0","summary":"来凯医药有限公司（股票代码：02105）于2026年5月11日发布公告称，公司于2026年5月8日分别发行普通股1,200,000股和1,665,000股，合计2,865,000股，全部用于满足依据2024年股份奖励计划授予的限制性股票单位（RSU）归属。两次发行分别占变动前已发行股本的约0.2688%和0.3729%，合计占变动前已发行股本的约0.64%，发行价格均为每股0港元。\n本次股份发行完成后，公司已发行股本由原先的446,466,350股增加至449,331,350股。公司确认已遵守包括香港联合交易所有限公司证券上市规则在内的所有适用法律及监管规定。该公告由联席公司秘书柯晨煜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"来凯医药-B：根据2024年股份奖励计划发行2,865,000股新股，已发行股本增至449,331,350股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633539754","title":"来凯医药-B(02105)授出合共1532.35万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2633539754","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633539754?lang=zh_cn&edition=full","pubTime":"2026-05-08 19:33","pubTimestamp":1778240038,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)公布，于2026年5月8日，根据2024年股份奖励计划向承授人( 包括三名执行董事 )授出合共1532.35万份受限制股份单位( 相当于合共1532.35万股股份 )。向包括吕向阳博士、 谢玲女士及顾祥巨博士在内的三名执行董事授出受限制股份单位须待独立股东在股东周年大会上批准后，方可作实。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633190028","title":"港股异动 | 来凯医药-B(02105)尾盘涨超5% 齐鲁制药将推进LAE002国内上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2633190028","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633190028?lang=zh_cn&edition=full","pubTime":"2026-05-07 15:23","pubTimestamp":1778138614,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B尾盘涨超5%，截至发稿，涨3.83%，报13.82港元，成交额2591万港元。公开资料显示，LAE002是来凯医药自主开发的一种AKT强效抑制剂。根据来凯医药与齐鲁制药所签协议，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。此外，来凯医药有权基于中国地区该药物的未来净销售额收取销售分成，分成比率在十余个至二十余个百分点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105","BK4588","VXUS","BK1191","IPOS","01477","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117728485","title":"来凯医药-B更新2026年4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1117728485","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117728485?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:12","pubTimestamp":1778058740,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年5月6日发布截至2026年4月30日止的股份变动月报表。报告显示，公司本月内未发生新增股份发行、回购或注销行为，整体股本状况保持不变。在期权与激励计划方面，首发前购股权计划本月内有70,000股期权失效，期末剩余24,690,130股期权。首发后购股权计划本月合计未有行使或授出新股，合计仍可发行及转让16,630,035股。截至2026年4月末，公司股本总数保持不变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628906507","title":"中金：维持来凯医药-B(02105)跑赢行业评级 目标价27.02港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628906507","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628906507?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:36","pubTimestamp":1776649015,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，来凯医药-B和齐鲁制药达成合作的首付款收入，维持跑赢行业评级，基于DCF模型，维持目标价27.02港币不变，较当前股价有48.9%的上行空间。2025年11月，公司公告将LAE002以20.45亿元首付款和里程碑，外加百分之十几到二十几的分成将中国地区权益授权给齐鲁制药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473918","title":"来凯医药-B(02105)：LAE 002(Afuresertib)III期临床试验(AFFIRM-205)达到无进展生存期(PFS)的主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627473918?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:22","pubTimestamp":1776212528,"startTime":"0","endTime":"0","summary":"II期临床试验是一项多中心、随机、双盲、安慰剂对照的关键性研究，旨在评估该联合疗法的抗肿瘤疗效及安全性。.每日一次口服LAE 002的治疗，患者耐受性良好，因不良事件而中止治疗的比例极低。本集团有权就许可区域内LAE 002的未来净销售额收取梯度销售分成，分成比率在十余个百分点至二十余个百分点。本集团计划在中国以外地区寻求战略合作伙伴，以加速LAE 002在国际市场的开发及商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK4195","III","02105","BK4211","BK1161","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187572464","title":"来凯医药-B2025年收入突破1亿元 现金储备与研发双动能显著提升","url":"https://stock-news.laohu8.com/highlight/detail?id=1187572464","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187572464?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:29","pubTimestamp":1776072544,"startTime":"0","endTime":"0","summary":"来凯医药-B于2025年度在肥胖及肿瘤等核心领域取得多项进展，并因授权协议首次实现超过1亿元人民币的收入，整体经营与财务结构出现明显变化。受该笔收入带动，公司2025年年内亏损为人民币2.29亿元，较2024年的2.54亿元有所收窄。全年毛利达人民币0.86亿元。2025年研发费用为人民币2.50亿元，较上年度的2.15亿元增长16.2%。截至2025年12月31日，公司总资产约人民币14.15亿元，较2024年末显著增长；现金及现金等价物增至人民币12.41亿元，同比几近翻倍。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136025323","title":"来凯医药-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1136025323","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136025323?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:11","pubTimestamp":1775121101,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年4月2日公布截至2026年3月31日的股份变动月报表。期末已发行股份数为446,466,350股，与上月底持平，未进行任何新的发行、购回或注销活动，亦无库藏股变动。在股权激励方面，首次公开发售前购股权计划维持24,760,130份期权，未发生行使或失效；首次公开发售后购股权计划本月无新增授出或行使，未来最多可发行16,630,035股。公司声明已遵守香港联交所《上市规则》及相关法律法规，并已就所有发行及转让事宜获得董事会批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620232095","title":"来凯医药-B(02105)2025年实现收益约1.07亿元 研发费用同比增长16.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620232095","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620232095?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:55","pubTimestamp":1773831316,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 公布2025年业绩，实现收益约1.07亿元，毛利8641.9万元，研发费用约2.5亿元，同比增长16.17%;净亏损约2.29亿元，同比收窄9.82%。公告称，2025年的收益来源于与齐鲁制药进行的LAE002的对外授权交易。研发费用增长主要是由于ActRII产品组合的相关费用增加，及以权益结算的股份支付的付款开支增加。截至2025年12月31日，公司已针对LAE102、LAE103、LAE002、LAE001及LAE005启动七项临床试验，以解决肥胖症及癌症领域未被满足的医疗需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132876590","title":"来凯医药-B(02105)2025年度授权收入推动营收增长 亏损收窄 资金状况稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=1132876590","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132876590?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:49","pubTimestamp":1773830953,"startTime":"0","endTime":"0","summary":"来凯医药有限公司截至2025年12月31日止年度录得收入人民币106,719千元，主要来自与齐鲁制药签订对外授权交易所产生的许可收入。销售成本为人民币20,300千元，带动报告期内实现毛利人民币86,419千元。研发投入持续保持高水平，年内研究费用达到人民币249,901千元，相比2024年的人民币215,115千元有所上升；行政开支亦自上一年度的人民币74,115千元增至人民币106,478千元，主要受以权益结算的股份支付及相关开支增加所致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":-0.0502},{"period":"1month","weight":-0.3054},{"period":"3month","weight":-0.3664},{"period":"6month","weight":-0.4013},{"period":"1year","weight":-0.5869},{"period":"ytd","weight":-0.3029}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.264392},{"month":2,"riseRate":0.666667,"avgChangeRate":0.234103},{"month":3,"riseRate":0.666667,"avgChangeRate":0.090739},{"month":4,"riseRate":0.333333,"avgChangeRate":0.001974},{"month":5,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":6,"riseRate":0,"avgChangeRate":-0.147755},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.063454},{"month":8,"riseRate":0.666667,"avgChangeRate":0.069227},{"month":9,"riseRate":0.666667,"avgChangeRate":0.04052},{"month":10,"riseRate":0.666667,"avgChangeRate":0.10793},{"month":11,"riseRate":1,"avgChangeRate":0.401946},{"month":12,"riseRate":0,"avgChangeRate":-0.176326}],"exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}